SCN9A Antibody

Code CSB-PA003362
Size US$100
Order now
Image
  • Western Blot analysis of 293T cells using Na+ CP type IXα Polyclonal Antibody
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
SCN9A
Alternative Names
ETHA antibody; GEFSP7 antibody; hNE Na antibody; hNE-Na antibody; hNENa antibody; NE NA antibody; NENA antibody; Neuroendocrine sodium channel antibody; Peripheral sodium channel 1 antibody; PN1 antibody; Scn9a antibody; SCN9A_HUMAN antibody; Sodium channel protein type 9 subunit alpha antibody; Sodium channel protein type IX subunit alpha antibody; Sodium channel voltage gated type IX alpha antibody; Sodium channel voltage gated type IX alpha polypeptide antibody; Sodium channel voltage gated type IX alpha subunit antibody; Voltage gated sodium channel alpha subunit Nav1.7 antibody; Voltage gated sodium channel subunit alpha Nav1 antibody; Voltage-gated sodium channel subunit alpha Nav1.7 antibody
Raised in
Rabbit
Species Reactivity
Human,Mouse,Rat
Immunogen
Synthesized peptide derived from the Internal region of Human Na+ CP type IXα.
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Isotype
IgG
Purification Method
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Form
Liquid
Tested Applications
WB, IHC, ELISA
Recommended Dilution
Application Recommended Dilution
WB 1:500-1:2000
IHC 1:100-1:300
ELISA 1:40000
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
Mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-sensitive Na(+) channel isoform. Plays a role in pain mechanisms, especially in the development of inflammatory pain.
Gene References into Functions
  1. Nav1.7 is a substrate for Fyn kinase. PMID: 29790812
  2. This study demonstrated that the higher expression Nav1.7 in human Dorsal Root Ganglion Neurons. PMID: 28424991
  3. cross-talk between distinct CRMP2 posttranslational modifications is a key factor in determining NaV1.7 trafficking and localization PMID: 27940916
  4. Hereditary Small fiber neuropathy has been described with pathogenic mutations in sodium channels [Nav1.7 (mostly), which lead to hyperexcitability of dorsal root ganglions. These gain-of-function mutations result in degeneration of small fibers. PMID: 28639956
  5. Genetic polymorphisms of SCN9A are associated with protection for severe neuropathy induced by oxaliplatin in digestive cancer. PMID: 28103821
  6. the results of this study provide mechanistic evidence for a time-dependent increase in intracellular [Ca2+]i and energetic compromise in the neurites of dorsal root ganglia neurons expressing G856D mutant Nav1.7 channels. PMID: 27821467
  7. the FGF13/Nav1.7 complex is essential for sustaining the transmission of noxious heat signals PMID: 28162808
  8. This study showed that gain-of-function attributes at the channel level and differential effects of physiologically relevant thermal stimuli on the excitability of DRG neurons expressing mutant and WT Nav1.7 channels, suggesting a cellular mechanism for warmth-triggered pain episodes in Erythromelalgia patients. PMID: 27413160
  9. The four congenital insensitivity to pain families, while not closely related, belong to the same ethnic group and clan, and the SCN9A mutation may be specific, if not unique to this group PMID: 27747863
  10. A novel Nav1.9 mutation, p.Arg222His, was identified in patients with early-onset pain in distal extremities including joints and gastrointestinal disturbances, but was absent from an asymptomatic blood relative. PMID: 27503742
  11. Gain-of-function mutation of a voltage-gated sodium channel NaV1.7 associated with peripheral pain and impaired limb development PMID: 28381558
  12. Results indicate that Nav 1.7 promotes gastric cancer progression through MACC1-mediated upregulation of NHE1. PMID: 27529686
  13. This is the first study to demonstrate that binding of ProTx-II to the lipid membrane is directly linked to its potency as an hNaV1.7 channel inhibitor. PMID: 27311819
  14. report the engineering of highly potent and selective inhibitors of the Nav1.7 channel based on tarantula ceratotoxin-1 (CcoTx1). We utilized a combination of directed evolution, saturation mutagenesis, chemical modification, and rational drug design to obtain higher potency and selectivity to the Nav1.7 channel PMID: 27129258
  15. Mutant cycle analysis with modified saxitoxins reveals specific interactions critical to attaining high-affinity inhibition of human NaV1.7. PMID: 27162340
  16. Postoperative pain was affected by SCN9A genetic variability in gynecological surgical patients. PMID: 26752484
  17. Patients with the SCN9A mutation with inherited erythromelalgia were characterized for the pain phenotype among individuals. PMID: 26920677
  18. These findings provided evidence that the variability of basal pain sensitivity was associated with SCN9A polymorphisms in the general population. PMID: 26168879
  19. Nav1.7 deletion has profound effects on gene expression, leading to an upregulation of enkephalin precursor Penk mRNA and met-enkephalin protein in sensory neurons. PMID: 26634308
  20. Association of SCN9A variants with neuropathic pain and pain severity suggests a role of SCN9A in the disease etiology of neuropathic pain PMID: 25585270
  21. We report the case of a 6-year-old girl with a SCN9A mutation who presented with both gain of function and loss of function phenotypes, including congenital corneal anesthesia. PMID: 26486037
  22. the activity of mutant Nav1.7 channels in smooth muscle cells of skin vasculature and innervating sensory and sympathetic fibers contribute to the skin reddening PMID: 25957174
  23. The co-segregation of the I739V variant in the affected members of the family provides evidence, for the first time, that paroxysmal itch can be related to a mutation in sodium channel gene. PMID: 24820863
  24. Novel SCN9A mutations altering Nav1.7 channel activation were found families with inherited erythromelalgia, paroxysmal extreme pain disorder and congenital insensitivity to pain. PMID: 25995458
  25. NaV1.7 is expressed in both dorsal root ganglion neurons and pancreatic beta cells.Vulnerability of dorsal root ganglia neurons due to NaV1.7 mutations increases risk of neuropathy. PMID: 25008557
  26. Our study demonstrates an example of predicting the treatment effect of mexiletine in patients suffering from a specific gain-of-function mutation in NaV1.7 PMID: 24866741
  27. Nav1.7 mutations are associated with pain syndromes including erythromelalgia. PMID: 25575597
  28. The novel p.L1612P Nav1.7 mutation expands the paroxysmal extreme pain disorder spectrum with a unique combination of clinical symptoms and electrophysiological properties PMID: 25285947
  29. PKC can increase sodium resurgent currents through phosphorylation of a conserved Serine residue located in the domain III-IV linker of hNav1.7 PMID: 25240195
  30. Sodium channel Nav1.7, encoded by SCN9A, is expressed in DRG neurons and regulates their excitability. PMID: 25209274
  31. Recent studies have shown that mutations in the SCN9A gene are the cause of a subgroup of idiopathic small fiber neuropathies and that polymorphisms of SCN9A are associated with an increase in susceptibility to pain. PMID: 24202110
  32. This study show a linear correlation between the level of Nav1.7 conductance and current threshold in DRG neurons. PMID: 24401712
  33. EGF/EGFR-mediated upregulation of Nav1.7 is necessary for invasive behaviour in these cells. PMID: 23986482
  34. A working link between nociception and olfaction via Nav1.7 in the gain-of-function direction. PMID: 23874707
  35. persistent and resurgent currents are likely to determine whether a mutation in Nav1.7 leads to IEM or PEPD. PMID: 24311784
  36. This study demonstrated that a variant of NaV1.7 associated with painful neuropathy depolarizes resting membrane potential and produces an enhanced inward current during interspike intervals, thereby contributing to DRG neuron hyperexcitability PMID: 23850641
  37. Role of the SCN9A mutations in genetic epilepsy with febrile seizures plus and Dravet syndrome PMID: 23895530
  38. 2 gain-of-function mutations in the 4th domain of Nav1.7, A1746G & W1538R, caused hyperpolarization and affected age of erythromelalgia onset. PMID: 23292638
  39. Data indicate that micro-SLPTX-Ssm6a, a unique 46-residue peptide from centipede venom, potently inhibits NaV1.7. PMID: 24082113
  40. a novel regulatory mechanism that utilizes CRMP2 SUMOylation to choreograph NaV1.7 trafficking. PMID: 23836888
  41. More patients have suffered dyskinesis pain. A 3448 (C/T) mutation of SCN9A gene may be related to pathogenesis of pain in Parkinsonism. PMID: 23450472
  42. A novel SCN9A mutation responsible for primary erythromelalgia and is resistant to the treatment of sodium channel blockers. PMID: 23383113
  43. Structural and functional demonstration of the importance of radial tuning of the sodium channel S6 helix for the channel activation. PMID: 23536180
  44. Patients carrying the SCN9A 3312Tallele presented with lower postoperative pain sensitivity in the presence of a similar surgical pain stimulus PMID: 23364568
  45. We identified a novel homozygous mutation in SCN9A from 2 Japanese families with autosomal recessive hereditary sensory and autonomic neuropathy type IId. PMID: 23596073
  46. We also found a splicing junction variant of SCN91 in all 19 patients WITH enital insensitivity to pain PMID: 23129781
  47. In small-fiber neuropathy, [isoleucine]228[methionine] variant Nav1.7 channel contributes to impaired regeneration and degeneration of sensory axons. PMID: 23280954
  48. Structural modelling reveals that Na(v)1.7-S241T is ~2.4 A apart from V400M in the folded channel, and thermodynamic analysis demonstrates energetic coupling of V400M and S241T during activation. PMID: 23149731
  49. These data strongly suggest that pain perception in at least a subset of patients with interstitial cystitis/bladder pain syndrome is influenced by the rs6746030 polymorphism in the SCN9A voltage-gated sodium channel. PMID: 23102778
  50. Splicing can change the way that Na(V) channels interact with beta subunits. PMID: 22911851

Show More

Hide All

Involvement in disease
Primary erythermalgia (PERYTHM); Indifference to pain, congenital, autosomal recessive (CIP); Paroxysmal extreme pain disorder (PEPD); Generalized epilepsy with febrile seizures plus 7 (GEFS+7); Febrile seizures, familial, 3B (FEB3B)
Subcellular Location
Cell membrane; Multi-pass membrane protein. Cell projection, neuron projection.
Protein Families
Sodium channel (TC 1.A.1.10) family, Nav1.7/SCN9A subfamily
Tissue Specificity
Expressed strongly in dorsal root ganglion, with only minor levels elsewhere in the body, smooth muscle cells, MTC cell line and C-cell carcinoma. Also expressed in vagus nerves within the head and neck region. Isoform 1 is expressed preferentially in the
Database Links

HGNC: 10597

OMIM: 133020

KEGG: hsa:6335

STRING: 9606.ENSP00000386306

UniGene: Hs.439145

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*